低剂量辅助甲基环己亚硝脲相关的肺纤维化
Pulmonary fibrosis associated with low-dose adjuvant methyl-CCNU.
作者信息
Block M, Lachowiez R M, Rios C, Hirschl S
机构信息
Regional Cancer Center, Lourdes Hospital, Binghamton, New York.
出版信息
Med Pediatr Oncol. 1990;18(3):256-60. doi: 10.1002/mpo.2950180320.
Pulmonary fibrosis is a serious side effect of nitrosourea therapy, occurring most frequently in patients treated with BCNU. Pulmonary fibrosis developed in a 63 year-old male patient while being treated with adjuvant methyl-CCNU for rectal carcinoma. This toxicity is rare with methyl-CCNU, having only been reported once previously. The case of methyl-CCNU-induced pulmonary fibrosis reported here occurred at a much lower total dose than the first reported case (604 mg/m2 vs. 2,733 mg/m2). Details of the case history, including radiographic and pathologic findings, are presented.
肺纤维化是亚硝基脲疗法的一种严重副作用，最常发生于接受卡氮芥治疗的患者中。一名63岁男性患者在接受辅助性甲基环己亚硝脲治疗直肠癌时发生了肺纤维化。这种毒性在甲基环己亚硝脲治疗中较为罕见，此前仅报告过一例。本文报告的甲基环己亚硝脲诱发肺纤维化病例的总剂量远低于首例报告病例（604mg/m² 对比2733mg/m²）。文中呈现了该病例的详细病史，包括影像学和病理学检查结果。
Zotero 插件